AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 121 min read$QNRX

BTIG initiates coverage of Quoin Pharmaceuticals with Buy rating, $14 price target

BTIG initiated coverage of Quoin Pharmaceuticals with a Buy rating and $14 price target, implying a 211.1% upside from the Oct 9 close of $4.50. The firm cited strong clinical data for QRX003 in treating Netherton Syndrome and a significant market opportunity exceeding $3 billion.

Original reporting
tradingview.com
Published Oct 12, 2026, 10:19 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 10:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
BTIG initiates coverage of Quoin Pharmaceuticals with Buy rating, $14 price target — source image
Source · tradingview.com
Decision brief

The 30-second read

$QNRXBullishMed
01

Why it matters

The note could attract new capital and increase volatility.

02

Market read

First analyst rating for QNRX, likely to influence short‑term price action.

03

What to watch

Potential regulatory delays or competition could temper upside.

Relevance 7/10Novelty 7/10Timing: today

Background

BTIG’s new coverage adds a fresh analyst perspective on Quoin Pharmaceuticals.

Company-level read

Ticker impact

$QNRXBullishHigh confidence
Context

BTIG initiated coverage with a Buy rating and a $14 price target, implying a 211% upside from the recent close.

Expected impact

upward pressure as investors price in the new target

Evidence & confidence

The coverage is the first BTIG note on QNRX and sets a substantially higher valuation than current market price.

Market effects

Sector

Positive signal may lift sentiment in the rare‑disease biotech sector.

Regional

Limited to U.S. biotech investors.

Global

Minimal beyond niche biotech community.

Counterpoint

What could challenge this read

The clinical data are early‑stage; the target may be overly optimistic.

Key entities

  • company
    Quoin Pharmaceuticals

    Biotech firm developing QRX003 for Netherton Syndrome.

  • analyst_firm
    BTIG

    Investment bank providing the coverage and price target.

Read at source← All news

Related articles

SEP 22
$QNRXMedAI 8/10

Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Quoin Pharmaceuticals Ltd. (QNRX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome – First-Ever Fast Track Designation Granted for a Peeling Skin Syndrome Therapy – Second Fast Track Designation Granted to QRX003, in Addition to Netherto

SEC EDGAR 8-K2 min
SEP 8
$QNRXMedAI 8/10

CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome

Quoin Pharmaceuticals (QNRX) announced FDA granted Rare Pediatric Disease Designation for QRX003, its treatment for Peeling Skin Syndrome. This is the second such designation for QRX003, following one for Netherton Syndrome. If approved, Quoin may receive a Priority Review Voucher. The company plans to initiate a Phase 2 study in 2H 2026, enrolling up to 12 patients. There are currently no approved treatments for Peeling Skin Syndrome.

globenewswire.com2 min
AUG 28
$AEMDHighAI 8/10

Biotech Gainers: QNRX Leads Gains As AEMD, DWTX And FRNM Report Key Developments

Aethlon Medical (AEMD) reported a 12% narrower Q1 loss and progress in its Hemopurifier study, with shares up 17.5%. Quoin Pharmaceuticals (QNRX) surged 34% pre-market on positive QRX003 data and a $50M financing. Dogwood Therapeutics (DWTX) gained 12% as its Halneuron trial advances. Freenome (FRNM) rose 7% after FDA Breakthrough Device Designation for its lung cancer test.

rttnews.com3 min